Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CEA CAR T cells

A preparation of T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CEA CAR T cells specifically recognize and induce selective toxicity in CEA-expressing tumor cells. CEA, a member of the CEA family of proteins, plays a key role in cell migration, cell invasion and cell adhesion, and is overexpressed by a variety of cancer types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-CEA-CAR T lymphocytes CEA CAR T cells

anti-CEA CAR T cells

Search NCI's Drug Dictionary